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Abstract- Clofibrate is a glucuronosyl transferase inducer that has been proposed to increase the elimination 
of bilirubin in neonates with hyperbilirubinemia. This study was conducted to determine the therapeutic effect 
of clofibrate in term neonates with non-hemolytic jaundice. This study was conducted on 52 newborns with 
pathologic unconjugated jaundice in Qazvin children hospital. Newborns divided randomly in two groups.  
Case group treated with clofibrate and intensive phototherapy, while control group treated only with intensive 
phototherapy. Serum bilirubin level was measured before and 6, 12, 24 and 48 hours after treatment. Results 
were compared and analyzed. The mean serum level of bilirubin before treatment in the case and control 
groups were 20.78±2.38 and 20.52±2.44 mg/dl, respectively (P=0.69). The mean serum level of bilirubin in 
6, 12, 24 and 48 hours after treatment in the case group were 18.20±2.20, 14.70±2.06, 10.72±2.40 and  
8.90±0.83 mg/dl , respectively. These values in control group were 18.26±2.42, 15.36±2.59, 12.29±2.28 and 
10.23±1.50 mg/dl, respectively. There was significant difference between two groups regarding mean serum 
level of bilirubin 24 hours (P=0.019) and 48 hours after treatment (P=0.005). In conclusion, clofibrate was 
effective in reducing neonatal jaundice and its effect appeared 24 hours after treatment.  
© 2012 Tehran University of Medical Sciences. All rights reserved.  
Acta Medica Iranica, 2012; 50(1): 21-25.  
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Introduction 
 
Neonatal jaundice is a common disease in neonates. 
Based on current statistics 60% of term neonates and 
80% of preterm neonates suffer from jaundice during the 
first week of birth (12,15,22). Although the disease 
usually has a good prognosis, but in cases where its 
intensity increases, can cause irreversible lesions of the 
central nervous system (Kernicterus) (2,13,19). 
Different method of therapy such as phototherapy and 
blood exchange are used to treat jaundice and prevent 
kernicterus (12,15,22). Phototherapy is the most 
common therapeutic method. Although today the use  of 
photo blanket at home have made outpatient treatment 
of neonates possible, still many neonates have to be 
hospitalized receiving phototherapy. This method of 
treatment is followed by hospitalization cost, risk of 
nosocomial infections and losing social activity of 
parents (12,22). Exchange transfusion is recommended 
when phototherapy fail to reduce unconjugated bilirubin 
(12,15,22). Mortality of exchange transfusion, even If 
done by experts physician is about 0.3 per thousand. In 
addition this procedure may results in many early and 
late complications (15). Many drugs such as 
Phenobarbital, intravenous immunoglobulin (IVIG), D-
penicillamine, metalloporphyrins and Sn-mesoporphyrin 
have been used in treatment of pathologic unconjugated 
hyperbilirubinemia (1,5,16). The study of Mohammad 
Zadeh and colleagues showed that clofibrate is effective 
in the treatment of unconjugated hyperbilirubinemia 
(14). The present study was conducted to determine the 
efficacy of clofibrate in the treatment of pathologic 
unconjugated hyperbilirubinemia of neonates in Qazvin 
children hospital (Qazvin province, Iran).  
 
Materials and Methods 
 
This single blind clinical trial study was performed on 
52 neonates with pathologic unconjugated 
hyperbilirubinemia in Qazvin children's hospital, in 
2007. This hospital is affiliated to Qazvin University of 
Medical Sciences. Qazvin is a historical city 140 
kilometers away from Tehran (Iran). Inclusion criteria in 
case and control groups included: 1) Term neonate 
(gestational age between 38-41 weeks). 2) Weight 
between 2500-4000 g. 3) Age between 2-7 days. 4) 
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Serum total bilirubin level between 17-26 mg/dl with 
priority of unconjugated bilirubin. 5) Level of direct 
bilirubin less than 2 mg/dl or less than 15% of total 
serum bilirubin. 6) Exclusive breast feeding. 
Premature neonates and neonates with diseases such 
as sepsis, meningitis, congenital anomalies, dehydration, 
hemolytic diseases and conjugated hyperbilirubinemia 
were excluded. Hemolytic diseases included RH and 
blood incompatibility and G6PD deficiency. Neonates 
were randomly divided in case and control groups. 
Samples were selected in sequence. Placing in case or 
control groups was based on randomly numbers table. 
Case group were treated by clofibrate and intense 
phototherapy, while control group treated only by 
intense phototherapy. Clofibrate was administered as a 
single dose of 100 mg/kg as pearl. Neonates who 
vomited after taking the drug were excluded. Clofibrate 
was made by Zahravi Company (Tehran, Iran) with 
batch number: 196 and registered number: 1228098598. 
Intense phototherapy was done by blue light with 8 
lamped set Tusan model (made in Iran). The lamps were 
with brand name of Philips (20 watt lamp and 2500 
hours lifetime). The distance of lamps from patients was 
25cm approximately. Phototherapy was carried out in 
compliance with all standard conditions. Both groups 
were matched in terms of gender, age, weight and initial 
bilirubin (on admission). Bilirubin levels in both groups 
were measured before and after treatment. In addition it 
was also measured 6, 12, 24 and 48 hours after starting 
phototherapy. Bilirubin was measured by spectrometry 
method with autoanalyser, Technicon RA 1000 model 
(Technicon Instrument Corporation, Tarry town, New 
York, USA). Phototherapy was stopped when serum 
bilirubin level met lower than 10mg/dl. Besides serum 
bilirubin level, hemoglobin, hematocrit, reticulocyte, 
G6PD, direct coombs test and peripheral blood smear 
were tested. In addition, mother and neonate blood 
groups were checked .The results of two groups were 
compared and analyzed by Chi-square and students t test 
using SPSS software. P-value less than 0.05 was 
considered significant.  
 
Ethics 
All parents were given clear explanations regarding 
the methodology of the research and also lack of any 
harmful effect due to the dose of clofibrate administered. 
The present study was ethically confirmed by ethical 
committee of Qazvin University of Medical Sciences 
with code: 154. The neonates were included in the study 
only if their parents were satisfied and signed the 
consent form.  
 
Results 
 
Of 52 neonates, 26 (11 girls and 15 boys) treated with 
clofibrate and intense phototherapy (case group) and 26 
(11 girls and 15 boys) treated with only intense 
phototherapy (control group). There was no significant 
difference between two groups regarding gender, age 
and weight. In addition, serum level of conjugated and 
total bilirubin (on admission) also showed no significant 
difference (Table 1) (P>0.05). 
 The mean serum level of bilirubin 6, 12, 24 and 48 
hours after treatment in case group were 18.20±2.20, 
14.70±2.06, 10.72±2.40 and 8.90±0.83 mg/dl, 
respectively. These values in control group were 
18.26±2.42, 15.36±2.59, 12.29±2.28 and 10.23 1.50 
mg/dl, respectively. There was significant difference 
between two groups regarding mean serum level of 
bilirubin 24 hours (P=0.019) and 48 hours after 
treatment (P=0.005) (Table 2, Figure 1). 
The rates of bilirubin decline in case and control 
groups were 0.247 and 0.215 mg/dl per hour, 
respectively. Serum bilirubin decline rate was higher in 
case group than the control group (12 to 48 hours after 
starting treatment) (Figure 1). None of neonates in case 
group required phototherapy more than 48 hours. On the 
other hand, phototherapy continued for more than 48 
hours in eight neonates of the control group.  
 
 
Table 1. Comparison of variables in case and control groups. 
Variables Case Group  
(Mean ± SD) 
Control Group 
(Mean ± SD) 
P 
Sex 11female, 15 male 11female, 15 male 1 
Age (day) 3.31±1.1 3.19±0.98 0.56 
Weight (g) 3057±301 3105±337 0.57 
TSB (on admission) mg/dl 20.78±2.38 20.52±2.44 0.69 
SCB (on admission) mg/dl 0.19±0.769 0.723±0.21 0.411 
TBS= Total serum bilirubin 
SBC= Serum conjugated bilirubin 
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Table 2. Comparison of serum bilirubin level in case and control groups. 
Hour   
                           
 Group N 
Serum bilirubin level 
(Mean± SD) 
P 
95% confidence interval 
Lower Upper 
0 Case 
Control 
26 
26 
20.788±2.3852 
20.523±2.4458 
0.69 -1.0803 
-1.0803 
1.6111 
1.6111 
6 Case 
Control 
26 
26 
18.200±2.2062 
18.265±20.4287 
0.91 -1.3578 
-1.3581 
1.2271 
1.2274 
12 Case 
Control 
26 
26 
14.700±2.0684 
15.362±2.5909 
0.31 -1.9675 
-1.9691 
0.6444 
0.6460 
24 Case 
Control 
26 
26 
10.723±2.4052 
12.296±2.2871 
0.019 -2.8805 
-2.8806 
-0.2657 
-0.2656 
48 Case 
Control 
14 
21 
8.907±0.8334 
10.233±1.5028 
0.005 -2.2258 
-2.1335 
-0.4266 
-0.5189 
 
 
 
 
 
Figure 1. Comparison of bilirubin levels in case and control groups. 
 
Discussion 
 
Hyperbilirubinemia is a common disease of neonates. 
The disease is divided into two types, unconjugated and 
conjugated. Unconjugated type is more common and the 
excessive increase may lead to irreversible brain damage 
(kernicterus) (12,15,22). 
Phototherapy and blood exchange have been used for 
many years for treatment and prevention of 
complications. Although these two methods are very 
effective, each has different complications (12,15,22). In 
recent years several studies have been carried out to 
evaluate the effectiveness of pharmacologic agents such 
as clofibrate in the treatment of neonatal 
hyperbilirobinemia (1,4,5,14,16). The purpose of these 
studies is to decrease exchange transfusion, hospital stay 
and health care costs. Studies have shown that  a dose of 
100 mg clofibrate per kg of body weight as single dose 
combined with phototherapy decreases serum bilirubin 
faster than phototherapy alone (1,14,16). In another 
study, clofibrate at a single dose of 50 mg per kg of 
body weight showed the same effect (18). In present 
study, clofibrate showed effect 24 hours after treatment. 
While in other studies effectiveness has been reported 
12 and 16 hours after administration of clofibrate (8,14). 
This difference can depend on factors such as age of the 
newborns and fullness of stomach. Clofibrate activates 
peroxisome proliferator-activated receptors (PPARs) 
and regulates plasma lipid by lowering very-low density 
lipoproteins. The drug is absorbed from the 
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gastrointestinal tract and rapidly hydrolyzed to active 
metabolite (clofibric acid). This active metabolite 
ultimately excreted through urine as conjugated 
glucuronide (3,20). Clofibrate, like sodium 
phenobarbital and Chinese herbal remedies is a strong 
stimulator of glucuronyltransferase. This process results 
in increased conjugation of bilirubin and ultimately 
excretion of bilirubin. The drug increases liver bilirubin 
clearance rate to 100% within 6 hours. Clofibrate does 
not cause drowsiness and respiratory depression in 
comparison with sodium phenobarbital. In addition, it 
results liver bilirubin clearance (3,5,10-12,20). 
Clofibrate does not increase the chance of neurotoxicity 
comparing Chinese herbal remedies (5). Although 
clofibrate intake in adults may cause complications such 
as nausea, vomiting, diarrhea, alopecia and itching, no 
complications have been reported following a single 
dose of the drug consumed in neonates (4,14). In the 
present study, no symptoms were observed in our 
patients during treatment and follow up. Lack of an 
appropriate placebo for control group was limitation of 
this study. So it is possible to use clofibrate in mild 
jaundice along with phototherapy according to results of 
this study. But we have to pay attention that 
administration of clofibrate dos not let us to postpone 
exchange transfusion in severe hyperbilirubinemia. 
More studies are required to evaluate probable long term 
complications of clofibrate. This drug can be used 
routinely in neonates if it is proved to be harmless. In 
conclusion, clofibrate was effective in reducing neonatal 
jaundice and its effect will appear 24 hours after 
treatment. More research in this regard is recommended. 
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